Regional Differences in Diagnosis Journey and Healthcare Utilization: Results from the International Map of Axial Spondyloarthritis (IMAS).

Autor: Garrido-Cumbrera M; Universidad de Sevilla, Health & Territory Research (HTR), Seville, Spain. mcumbrera@us.es.; Spanish Federation of Spondyloarthritis Patient Associations (CEADE), Madrid, Spain. mcumbrera@us.es., Poddubnyy D; Charité-Universitätsmedizin Berlin, Berlin, Germany.; German Rheumatology Research Centre, Berlin, Germany., Sommerfleck F; Sanatorio Julio Mendez, Buenos Aires, Argentina., Bundy C; Cardiff University, Cardiff, UK., Makri S; Cyprus League for People with Rheumatism (CYLPER), Nicosia, Cyprus., Correa-Fernández J; Universidad de Sevilla, Health & Territory Research (HTR), Seville, Spain., Akerkar S; Mumbai Arthritis Clinic, Mumbai, India., Lowe J; Axial Spondyloarthritis International Federation (ASIF), London, UK., Karam E; Canadian Spondylitis Association (CSA), Toronto, Canada., Navarro-Compán V; Hospital Universitario La Paz, IdiPaz, Madrid, Spain.
Jazyk: angličtina
Zdroj: Rheumatology and therapy [Rheumatol Ther] 2024 Aug; Vol. 11 (4), pp. 927-945. Date of Electronic Publication: 2024 Jun 07.
DOI: 10.1007/s40744-024-00672-3
Abstrakt: Introduction: To assess differences in the diagnosis journey and access to care in a large sample of patients with axial spondyloarthritis (axSpA) from around the world, included in the International Map of Axial Spondyloarthritis (IMAS).
Methods: IMAS was a cross-sectional online survey (2017-2022) of 5557 unselected patients with axSpA from 27 countries. Across five worldwide geographic regions, the patient journey until diagnosis and healthcare utilization in the last 12 months prior to survey were evaluated. Univariable and multivariable linear regression was used to analyze factors associated with higher healthcare utilization.
Results: Of 5557 participants in IMAS, the diagnosis took an average of 7.4 years, requiring more than two visits to HCPs (77.7% general practitioner and 51.3% rheumatologist), and more than two diagnostic tests [67.5% performed human leukocyte antigen B27 (HLA-B27), 64.2% x-ray, and 59.1% magnetic resonance imaging (MRI) scans]. North America and Europe were the regions with the highest number of healthcare professional (HCP) visits for diagnosis, while the lowest number of visits was in the Asian region. In the previous 12 months, 94.9% (n = 5272) used at least one healthcare resource, with an average of 29 uses per year. The regions with the highest healthcare utilization were Latin America, Europe, and North America. In the multiple linear regression, factors associated with higher number of healthcare utilization were younger age (b =  - 0.311), female gender (b = 7.736), higher disease activity (b = 1.461), poorer mental health (b = 0.624), greater functional limitation (b = 0.300), greater spinal stiffness (b = 1.527), and longer diagnostic delay (b = 0.104).
Conclusion: The diagnosis of axSpA usually takes more than two visits to HCPs and at least 7 years. After diagnosis, axSpA is associated with frequent healthcare resource use. Younger age, female gender, higher disease activity, poorer mental health, greater functional limitation, greater spinal stiffness, and longer diagnostic delay are associated with higher healthcare utilization. Europe and North America use more HCP visits and diagnostic tests before and after diagnosis than the other regions.
(© 2024. The Author(s).)
Databáze: MEDLINE
Externí odkaz:
Nepřihlášeným uživatelům se plný text nezobrazuje